Shares of Moderna Inc. MRNA, +0.22% were up 2.3% in premarket trading on Wednesday, the day after the company’s stock price hit an all-time high of $234.60 when the market closed on Tuesday.
Moderna has one authorized product, its two-dose, mRNA-based COVID-19 vaccine; the global success of its shot, along with BioNTech BNTX, -1.83% and Pfizer Inc.’s PFE, +0.15% COVID-19 vaccine, has opened the door for broader interest in mRNA technology. Moderna’s stock has soared 124.4% so far this year, while the S&P 500 SPX, +0.13% is up 14.2%.